Literature DB >> 15515016

Screening for family members of patients with nasopharyngeal carcinoma.

Wai-Tong Ng1, Tsz-Kok Yau, Raymond W H Yung, Wai-Man Sze, Abby H L Tsang, Ada L Y Law, Anne W M Lee.   

Abstract

Nasopharyngeal carcinoma (NPC) is well known for its peculiarly skewed distribution with highest incidence in Southern Chinese population. Familial aggregation is evident, hence screening for early detection is offered by oncology centers in Hong Kong to first-degree relatives of patients with NPC. During the period 1994-2001, 929 family members were screened in our center. The screenees were advised to attend an annual examination that includes serological test against Epstein Barr Virus (EBV), physical examination to exclude cervical lymphadenopathy and cranial nerve palsy, and endoscopic examination of the nasopharyngeal region. Two different methods were used for the serology test: indirect immuno-fluorescent (IF) test for IgA against viral capsid antigen; and starting in 1997 enzyme-linked immunosorbent assay (ELIZA) against nuclear antigen and viral capsid antigen. Twelve cases of nasopharyngeal carcinoma were diagnosed, giving a detection rate of 5/1,155 (433/100,000) person-year for male and 7/1,404 (499/100,000) person-year for female participants observed. The corresponding average annual incidence in Hong Kong during this period was 24.1 and 9.6 per 100,000, respectively. Forty-one percent of these detected cases had Stage I disease, whereas only 2% of patients referred to the department for primary treatment presented with such early disease. Six cases were detected at first visit, and all were EBV-positive. Another 78 screenees with positive serology at first visit were followed up for 204 person years, and thus far NPC was detected in 3 after an interval of 6-32 months. Of the 845 initially EBV-negative screenees followed up for 2,337 person-years, NPC was detected in 3 after an interval of 12-45 months. One showed sero-conversion at the time of diagnosis. We conclude that family members of known patients do show a substantially higher risk of developing NPC, and regular screening by current method improves the chance of early detection. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15515016     DOI: 10.1002/ijc.20672

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models.

Authors:  Cheuk Wai Choi; Michael C H Lee; Wai Tong Ng; Lai Yau Law; Tsz Kok Yau; Anne W M Lee
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

2.  Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.

Authors:  Kelly J Yu; Wan-Lun Hsu; Ruth M Pfeiffer; Chun-Ju Chiang; Cheng-Ping Wang; Pei-Jen Lou; Yu-Juen Cheng; Patti Gravitt; Scott R Diehl; Alisa M Goldstein; Chien-Jen Chen; Allan Hildesheim
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

3.  Magnetic resonance imaging for the detection of nasopharyngeal carcinoma.

Authors:  A D King; A C Vlantis; R K Y Tsang; T M K Gary; A K Y Au; C Y Chan; S Y Kok; W T Kwok; H K Lui; A T Ahuja
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

4.  Development of a time-resolved fluorescence immunoassay for Epstein-Barr virus Zta IgA antibodies in human serum.

Authors:  Juanjuan Chen; Tiancai Liu; Zhenhua Chen; Jingyuan Hou; Yingsong Wu; Ming Li
Journal:  Viral Immunol       Date:  2015-02-04       Impact factor: 2.257

5.  Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong.

Authors:  Wai Tong Ng; Cheuk Wai Choi; Michael C H Lee; Lai Yau Law; Tsz Kok Yau; Anne W M Lee
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

Review 6.  The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk.

Authors:  Elham Hassen; Ghandri Nahla; Noureddine Bouaouina; Lotfi Chouchane
Journal:  Mol Biol Rep       Date:  2009-05-17       Impact factor: 2.316

7.  Comparison of narrow-band imaging and conventional nasopharyngoscopy for the screening of unaffected members of families with nasopharyngeal carcinoma.

Authors:  Ching-Yin Ho; Kee-Tak Chan; Pen-Yuan Chu
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-23       Impact factor: 2.503

8.  Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.

Authors:  Dewi K Paramita; Jajah Fachiroh; Sofia M Haryana; Jaap M Middeldorp
Journal:  Clin Vaccine Immunol       Date:  2009-03-25

9.  Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening.

Authors:  Wai Tong Ng; Cheuk Wai Choi; Michael C H Lee; Siu Hong Chan; Tsz Kok Yau; Anne W M Lee
Journal:  Fam Cancer       Date:  2008-08-26       Impact factor: 2.375

10.  Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening.

Authors:  J Fachiroh; P R Prasetyanti; D K Paramita; A T Prasetyawati; D W Anggrahini; S M Haryana; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2008-02-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.